STING1 and cancer: The potential translational benefit of STING agonists or similar agents such as TLR agonists as a complement to surgery stem from their hypothesized mechanism of action: increasing IFN-I production by cancer cells or accessory stromal cells within the tumor to increase activating cytokine production and to stimulate effective antigen presentation leading to preserved or augmented anti-tumor T cell responses, counteracting the systemic inflammatory signals from surgery or radiation that support recruitment and expansion of suppressive MDSC, TAM, and Treg to the tumor.